Valeant Pharma (VRX) Posts non-GAAP EPS of $0.58; Raises FY09 EPS Guidance
More News related to VRX
- Valent Pharma (VRX) Shares Ride the Lightning, But Is the Storm Breaking? - Barron's (GSK)
- Oceanside Pharmaceuticals Announces Launch of Librax(R) AG
- Valeant Pharmaceuticals Highlights Taribavirin Phase IIb End of Study Data Presentation at American Association for the Study of Liver Disease (AASLD) Annual Meeting
- Valeant Pharma (VRX) Posts non-GAAP EPS of $0.58; Raises FY09 EPS Guidance
- Valeant Pharmaceuticals Reports Third Quarter Financial Results
Valeant Pharmaceuticals International (NYSE: VRX) reports Q3 non-GAAP EPS of $0.58, 9 cents better than the analyst estimate of $0.49. Revenue for the quarter was $220 million, which compares to the estimate of $193.53 million.
Raises FY09 EPS guidance to $2.10 - $2.20, up from $1.90 - $2.10.
Related Categories
EarningsGuidance
Stocks Mentioned
-0.29Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
